Clinical Trials
> Lung Cancer

EMR 100070-004

A Phase III open-label, multicenter trial of MSB0010718C versus Docetaxel  in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

SWOG 1400

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.

PM1183-C-003-14

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS).

E4512

A Phase III Double-Blinded Trial for Surgically Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

A081105

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small.

A151216

Genetic Testing For Patients with Resectable or Resected Lung Cancer: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).